Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Japanese shares jump on Fed's growth projection, Topix at 30-year high

Published 18/03/2021, 07:37
Updated 18/03/2021, 07:42
© Reuters.

TOKYO, March 18 (Reuters) - Japanese shares jumped on
Thursday, with the Topix index hitting a 30-year high, propelled
by the U.S. Federal Reserve's projection for a rapid economic
growth and pledge for low rates.
The broader Topix .TOPX advanced 1.23% to close at
2,008.51, crossing the 2,000 mark for the first time since May
1991. The Nikkei index jumped 1.01% to 30,216.75, its highest
close in three weeks.
"Investors have a lot of reasons to sell stocks at the end
of the fiscal year end March, but today their appetite for
making bets greatly exceeded the sell-off pressure," said
Takatoshi Itoshima, strategist at Pictet Asset Management.
"The Fed gave investors confidence by brushing off
uncertainties of the rate outlook by pledging to keep its
interest rate at close to zero."
The S&P 500 and Dow Jones Industrial Average closed at
record highs on Wednesday after the Fed said the U.S. economy is
heading for its strongest growth in nearly 40 years, fuelled by
massive federal fiscal stimulus and the roll-out of COVID-19
vaccines. .N In Japan, chip-related shares advanced, with Nikkei
heavyweights Tokyo Electron 8035.T jumping 2.72%, Fanuc
6954.T gaining 1.94% and Advantest 6857.T rising 3.32%.
The airliners gained, with ANA Holdings 9202.T and Japan
Airlines 9201.T rising 1.32% and 1.46%, respectively, as the
Japanese government's advisory panel on coronavirus
countermeasures approved a plan to let the state of emergency
expire in the Tokyo area as scheduled on March 21. Shikoku Electric Power 9507.T surged 5.26% after a media
report said a court ruled that the utility can resume operations
of its only nuclear reactor. Mitsubishi UFJ Financial Group 8306.T , up 5.15%, and
Toyota Motor 7203.T , which rose 4.12%, were the biggest
advancers on the Topix 30.
The underperformers among the Topix 30 were SoftBank Group
9984.T , down 1.73%, followed by Astellas Pharma 4503.T ,
losing 0.50%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.